Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima Sells 2,868 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 2,868 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $81.87, for a total transaction of $234,803.16. Following the transaction, the chief operating officer now directly owns 944,460 shares of the company’s stock, valued at $77,322,940.20. The trade was a 0.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $39.61, for a total transaction of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $76.72 on Friday. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The company’s fifty day moving average is $49.75 and its two-hundred day moving average is $51.44.

Analysts Set New Price Targets

TEM has been the topic of a number of analyst reports. William Blair lowered shares of Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Bank of America raised their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Guggenheim began coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $58.55.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. GF Fund Management CO. LTD. purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $108,000. Voloridge Investment Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $11,826,000. Two Sigma Advisers LP purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $625,000. ProShare Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $244,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $1,034,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.